Skip to main content
Atrás
CHSYF logo

China Medical System Holdings Limited

Calidad de datos: 100%
Sobrecompra
CHSYF
OTC Healthcare Drug Manufacturers - Specialty & Generic
$1.35
$0.00 (0.00%)
Cap. Mercado: 3.28B
Rango del Día
$0.93 $1.35
Rango de 52 Semanas
$0.93 $1.64
Volumen
110
Promedio 50D / 200D
$1.35 / $1.31
Cierre Anterior
$1.35

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Healthcare (627 pares)

Métrica Acción Mediana del Sector
P/E 2.3 0.3
P/B 0.2 2.9
ROE % 8.6 3.7
Net Margin % 18.1 3.8
Rev Growth 5Y % -1.0 10.0
D/E 0.0 0.2

Precio Objetivo de Analistas

No hay cobertura de analistas disponible

Estimaciones de Ganancias

Período EPS Est. Ingresos Est. Analistas
FY2028 $1.23
$1.11 – $1.31
 15 B 1
FY2027 $1.01
$0.91 – $1.07
 12 B 1
FY2026 $0.85
$0.76 – $0.90
 10 B 1

Puntos Clave

Revenue declined -1.03% annually over 5 years
Earnings declined -10.45% over the past year
Net margin of 18.13% shows strong profitability
Debt/Equity of 0.04 — conservative balance sheet
Generating 812.64M in free cash flow
P/E of 2.26 — trading at a low valuation

Crecimiento

Revenue Growth (5Y)
-1.03%
Revenue (1Y)7.11%
Earnings (1Y)-10.45%
FCF Growth (3Y)-48.20%

Calidad

Return on Equity
8.60%
ROIC6.37%
Net Margin18.13%
Op. Margin19.22%

Seguridad

Debt / Equity
0.04
Current Ratio6.33
Interest Coverage77.77

Valoración

P/E Ratio
2.26
P/B Ratio0.19
EV/EBITDA0.82
Dividend Yield0.03%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 7.11% Revenue Growth (3Y) -0.08%
Earnings Growth (1Y) -10.45% Earnings Growth (3Y) -22.27%
Revenue Growth (5Y) -1.03% Earnings Growth (5Y) -16.73%
Profitability
Revenue (TTM) 8.00B Net Income (TTM) 1.45B
ROE 8.60% ROA 7.55%
Gross Margin 71.50% Operating Margin 19.22%
Net Margin 18.13% Free Cash Flow (TTM) 812.64M
ROIC 6.37% FCF Growth (3Y) -48.20%
Safety
Debt / Equity 0.04 Current Ratio 6.33
Interest Coverage 77.77 Dividend Yield 0.03%
Valuation
P/E Ratio 2.26 P/B Ratio 0.19
P/S Ratio 0.41 PEG Ratio -1.51
EV/EBITDA 0.82 Dividend Yield 0.03%
Market Cap 3.28B Enterprise Value 1.26B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 8.00B 7.47B 8.01B 9.15B 8.34B
Net Income 1.45B 1.62B 2.40B 3.26B 3.02B
EPS (Diluted) 0.60 0.67 0.98 1.33 1.22
Gross Profit 5.72B 5.42B 6.08B 7.04B 6.25B
Operating Income 1.54B 1.73B 2.71B 3.55B 3.15B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 19.21B 18.05B 17.73B 17.75B 15.81B
Total Liabilities 1.66B 1.64B 2.17B 3.02B 2.96B
Shareholders' Equity 17.40B 16.31B 15.52B 14.59B 12.75B
Total Debt 690.43M 860.74M 1.30B 1.81B 1.71B
Cash & Equivalents 2.70B 3.71B 4.31B 4.38B 3.39B
Current Assets 9.30B 8.70B 8.79B 8.83B 7.38B
Current Liabilities 1.47B 1.52B 2.05B 2.88B 2.08B

Puntuaciones de Estrategias

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Deep Value Investing (Seth Klarman)
#702 of 827
23
Value Defensive Investing (Benjamin Graham)
#286 of 709
33

Actividad Reciente

Entró Deep Value Investing (Seth Klarman)
Mar 24, 2026
Entró Defensive Investing (Benjamin Graham)
Mar 24, 2026